Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience.
COVID-19 severity
SARS-CoV-2 infection
Sardinian population
alleles
glucose-6-phosphate dehydrogenase
haplotypes
human leukocyte antigen
immunogenetic background
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
09
2020
accepted:
18
11
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinical outcome. We recruited 619 healthy Sardinian controls and 182 SARS-CoV-2 patients. Thirty-nine patients required hospital care and 143 were without symptoms, pauci-symptomatic or with mild disease. For all participants, we collected demographic and clinical data and analyzed the HLA allele and haplotype frequencies. Male sex and older age were more frequent in hospitalized patients, none of whom had been vaccinated during the previous seasonal flu vaccination campaignes. Compared to the group of asymptomatic or pauci-symptomatic patients, hospitalized patients also had a higher frequency of autoimmune diseases and glucose-6-phosphate-dehydrogenase (G6PDH) deficiency. None of these patients carried the beta-thalassemia trait, a relatively common finding in the Sardinian population. The extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 [OR 0.1 (95% CI 0-0.6), Pc = 0.015] was absent in all 182 patients, while the HLA-C*04:01 allele and the three-loci haplotype HLA-A*30:02, B*14:02, C*08:02 [OR 3.8 (95% CI 1.8-8.1), Pc = 0.025] were more frequently represented in patients than controls. In a comparison between in-patients and home care patients, the HLA-DRB1*08:01 allele was exclusively present in the hospitalized patients [OR > 2.5 (95% CI 2.7-220.6), Pc = 0.024]. The data emerging from our study suggest that the extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 has a protective effect against SARS-CoV-2 infection in the Sardinian population. Genetic factors that resulted to have a negative influence on the disease course were presence of the HLA-DRB1*08:01 allele and G6PDH deficiency, but not the beta-thalassemic trait. Absence of influenza vaccination could be a predisposing factor for more severe disease.
Identifiants
pubmed: 33343579
doi: 10.3389/fimmu.2020.605688
pmc: PMC7746644
doi:
Substances chimiques
HLA-DRB1 Chains
0
HLA-DRB1*08:01 antigen
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605688Informations de copyright
Copyright © 2020 Littera, Campagna, Deidda, Angioni, Cipri, Melis, Firinu, Santus, Lai, Porcella, Lai, Rassu, Scioscia, Meloni, Schirru, Cordeddu, Kowalik, Serra, Ragatzu, Carta, Del Giacco, Restivo, Deidda, Orrù, Palimodde, Perra, Orrù, Conti, Balestrieri, Serra, Onali, Marongiu, Perra and Chessa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Virol. 2020 Jun 16;94(13):
pubmed: 32303592
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18680-5
pubmed: 19846760
Annu Rev Immunol. 2018 Apr 26;36:519-548
pubmed: 29394121
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
CNS Neurosci Ther. 2020 May;26(5):499-501
pubmed: 32266761
Front Immunol. 2020 May 28;11:1208
pubmed: 32574270
AIDS. 2006 Aug 1;20(12):1621-6
pubmed: 16868443
Cell Rep. 2020 Aug 11;32(6):108016
pubmed: 32755598
Sci Rep. 2019 Dec 13;9(1):19061
pubmed: 31836763
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
J Hum Genet. 2020 Jul;65(7):569-575
pubmed: 32372051
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Blood. 2008 Jan 1;111(1):16-24
pubmed: 18156501
Vaccines (Basel). 2020 Aug 23;8(3):
pubmed: 32842505
J Cardiovasc Electrophysiol. 2020 May;31(5):1003-1008
pubmed: 32270559
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Rev Immunogenet. 2000;2(3):433-48
pubmed: 11256749
Med Hypotheses. 2020 Sep;142:109827
pubmed: 32447232
Tissue Antigens. 1992 Oct;40(4):165-74
pubmed: 1471143
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Mol Sci. 2020 Jul 23;21(15):
pubmed: 32717807
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Crit Care. 2020 Sep 1;24(1):539
pubmed: 32873316
Hum Genomics. 2019 Jan 8;13(1):2
pubmed: 30621780
Pathog Glob Health. 2020 May;114(3):109-110
pubmed: 32286926
Front Immunol. 2018 Dec 19;9:2991
pubmed: 30619344
J Chin Med Assoc. 2020 Jun;83(6):521-523
pubmed: 32243269
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
J Clin Microbiol. 2006 Feb;44(2):359-65
pubmed: 16455884
Hum Immunol. 2009 Jul;70(7):527-31
pubmed: 19445991
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Emerg Microbes Infect. 2012 Sep;1(9):e23
pubmed: 26038429
J Infect Dis. 2004 Aug 1;190(3):515-8
pubmed: 15243926
PLoS One. 2016 Jan 08;11(1):e0146086
pubmed: 26744892
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
Int J Immunogenet. 2020 Aug;47(4):324-328
pubmed: 32623831
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Int Arch Allergy Appl Immunol. 1977;54(3):285-7
pubmed: 873627
Med Hypotheses. 2020 Oct;143:110014
pubmed: 32615501
Geroscience. 2020 Aug;42(4):1015-1019
pubmed: 32583231
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
J Hepatol. 2020 Aug;73(2):453-455
pubmed: 32283134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect Dis. 2008 Mar 15;197(6):812-6
pubmed: 18269318
Nature. 2005 Mar 17;434(7031):400-4
pubmed: 15772666
PLoS One. 2019 Dec 17;14(12):e0226615
pubmed: 31846493
BMC Med Genet. 2003 Sep 12;4:9
pubmed: 12969506
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508